Patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer

Tucatinib is an oral HER2-targeted therapy that was approved by the FDA in April 2020 for use in combination with trastuzumab and capecitabine for treatment of patients with previously treated HER2+ metastatic breast cancer (MBC). Prof. dr. Peter Kaufman from the University of Vermont Cancer Center, Burlington, VT, USA presented a retrospective cohort study in MBC patients treated with tucatinib in the real-world setting. Demographic and clinical characteristics of patients were discussed, as well as treatment patterns and clinical outcomes for tucatinib-based treatment.